Date: 2015-03-11
Type of information: Private placement
Company: BiolineRx (Israel)
Investors:
Amount: $28.75 million
Funding type: private placement
Planned used:
Others: * On March 11, 2015, BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced that it has closed its previously announced underwritten public offering of 14,375,000 American Depositary Shares (“ADSs”), each representing ten (10) of its Ordinary Shares, at a public offering price of $2.00 per ADS, for gross proceeds of $28.75 million. All of the ADSs in the offering were sold by BioLineRx. The amount of ADSs sold includes an additional 1,875,000 ADSs purchased by the underwriters pursuant to the over-allotment option granted to them by BioLineRx. JMP Securities acted as sole book-running manager for the offering. Roth Capital Partners acted as lead manager. Maxim Group LLC acted as co-manager. The ADSs were issued pursuant to a shelf registration statement that was previously filed with, and declared effective by, the Securities and Exchange Commission (SEC). * On March 6, 2015, BioLineRx announced that it has priced an underwritten public offering of 12,500,000 American Depositary Shares each representing ten of its Ordinary Shares, at a public offering price of $2.00 per ADS for gross proceeds of $25 million. All of the ADSs in the offering are to be sold by BioLineRx. Delivery of the ADSs is expected to occur on March 11, 2015. BioLineRx has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 ADSs to cover over-allotments, if any. * On March 5, 2015, BioLineRx announced that it has commenced an underwritten public offering of American Depositary Shares (\"ADSs\"), each representing ten (10) of its Ordinary Shares. All of the ADSs in the offering are to be sold by BioLineRx.
Therapeutic area:
